A Smartphone App for Real-Time Assessment of Malaria Prophylaxis Adverse Events
Background: Growth of international travel to malarial areas over the last decades has contributed to more travelers taking malaria prophylaxis. Travel-related symptoms may be wrongly attributed to malaria prophylaxis and hinder compliance. Here, we aimed to assess the frequency of real-time reporting of symptoms by travelers following malaria prophylaxis using a smartphone app. Method: Adult international travelers included in this single-center study (Barcelona, Spain) used the smartphone Trip Doctor® app developed by our group for real-time tracking of symptoms and adherence to prophylaxis. Results: Six hundred four (n = 604) international travelers were included in the study; 74.3% (449) used the app daily, and for one-quarter of travelers, malaria prophylaxis was prescribed. Participants from the prophylaxis group traveled more to Africa (86.7% vs. 4.3%; p < 0.01) and to high travel medical risk countries (60.8% vs. 18%; p < 0.01) and reported more immunosuppression (30.8% vs. 23.1% p < 0.01). Regarding symptoms, no significant intergroup differences were observed, and no relationship was found between the total number of malarial pills taken and reported symptoms. Conclusions: In our cohort, the number of symptoms due to malaria prophylaxis was not significantly higher than in participants for whom prophylaxis was not prescribed, and the overall proportion of symptoms is higher compared with other studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Telemedicine journal and e-health : the official journal of the American Telemedicine Association - (2024) vom: 12. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodriguez-Valero, Natalia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse events |
|---|
| Anmerkungen: |
Date Revised 12.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1089/tmj.2023.0200 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367058200 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367058200 | ||
| 003 | DE-627 | ||
| 005 | 20240114234933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/tmj.2023.0200 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1258.xml |
| 035 | |a (DE-627)NLM367058200 | ||
| 035 | |a (NLM)38215269 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodriguez-Valero, Natalia |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Smartphone App for Real-Time Assessment of Malaria Prophylaxis Adverse Events |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Background: Growth of international travel to malarial areas over the last decades has contributed to more travelers taking malaria prophylaxis. Travel-related symptoms may be wrongly attributed to malaria prophylaxis and hinder compliance. Here, we aimed to assess the frequency of real-time reporting of symptoms by travelers following malaria prophylaxis using a smartphone app. Method: Adult international travelers included in this single-center study (Barcelona, Spain) used the smartphone Trip Doctor® app developed by our group for real-time tracking of symptoms and adherence to prophylaxis. Results: Six hundred four (n = 604) international travelers were included in the study; 74.3% (449) used the app daily, and for one-quarter of travelers, malaria prophylaxis was prescribed. Participants from the prophylaxis group traveled more to Africa (86.7% vs. 4.3%; p < 0.01) and to high travel medical risk countries (60.8% vs. 18%; p < 0.01) and reported more immunosuppression (30.8% vs. 23.1% p < 0.01). Regarding symptoms, no significant intergroup differences were observed, and no relationship was found between the total number of malarial pills taken and reported symptoms. Conclusions: In our cohort, the number of symptoms due to malaria prophylaxis was not significantly higher than in participants for whom prophylaxis was not prescribed, and the overall proportion of symptoms is higher compared with other studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a atovaquone–proguanil | |
| 650 | 4 | |a digital participatory surveillance system | |
| 650 | 4 | |a m-health | |
| 650 | 4 | |a malaria prophylaxis | |
| 650 | 4 | |a medical apps | |
| 650 | 4 | |a real-time health recordings | |
| 650 | 4 | |a telemedicine | |
| 700 | 1 | |a Ledesma-Carbayo, Maria Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Martí-Soler, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Cuadrado Sanchez, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Vladimirov, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Camprubí-Ferrer, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Pinazo, Maria Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Losada, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Almuedo-Riera, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Roman, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Roldan-Torralvo, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a de Alba, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Valverde, Juan Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Luengo Oroz, Miguel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Telemedicine journal and e-health : the official journal of the American Telemedicine Association |d 2000 |g (2024) vom: 12. Jan. |w (DE-627)NLM110257731 |x 1556-3669 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/tmj.2023.0200 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 01 | ||